The estimated Net Worth of Emma Reeve is at least $1.63 million dollars as of 22 May 2023. Ms. Reeve owns over 9,768 units of Constellation Pharmaceuticals Inc stock worth over $292,382 and over the last 8 years she sold CNST stock worth over $238,256. In addition, she makes $1,102,580 as Chief Financial Officer, Senior Vice President et Treasurer at Constellation Pharmaceuticals Inc.
Emma has made over 15 trades of the Constellation Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 9,768 units of CNST stock worth $325,958 on 22 May 2023.
The largest trade she's ever made was exercising 65,626 units of Constellation Pharmaceuticals Inc stock on 6 November 2019 worth over $442,976. On average, Emma trades about 4,649 units every 40 days since 2016. As of 22 May 2023 she still owns at least 8,602 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of Ms. Reeve stock trades at the bottom of the page.
Emma Reeve serves as Chief Financial Officer, Senior Vice President, Treasurer of the Company. Prior to joining us, Ms. Reeve served as corporate controller of PAREXEL International, a life sciences consulting firm and contract research organization, from September 2014 to October 2017 and as interim chief financial officer and corporate controller of PAREXEL from July 2016 to May 2017, where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Ms. Reeve served as head of finance and administration at Novartis Pharma Schweiz, a pharmaceutical company, from May 2012 to August 2014 and as vice president, global head business planning and analysis for Novartis Vaccines and Diagnostics, a division of Novartis, from January 2008 to April 2012. She served as chief financial officer of Inotek Pharmaceuticals Inc., a development-stage biotechnology company, from 2006 to 2007. Ms. Reeve was senior director of research operations at Merck Research Laboratories from 2004 to 2006. Prior to that she served as chief financial officer of Aton Pharma, Inc., a development-stage biotechnology company, from 2002 to 2004. Ms. Reeve was at Bristol-Myers Squibb Company, a global biopharmaceuticals company, from 1994 to 2002. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.
As the Chief Financial Officer, Senior Vice President et Treasurer of Constellation Pharmaceuticals Inc, the total compensation of Emma Reeve at Constellation Pharmaceuticals Inc is $1,102,580. There are 1 executives at Constellation Pharmaceuticals Inc getting paid more, with Jigar Raythatha having the highest compensation of $2,306,720.
Emma Reeve is 59, she's been the Chief Financial Officer, Senior Vice President et Treasurer of Constellation Pharmaceuticals Inc since 2017. There are 2 older and 6 younger executives at Constellation Pharmaceuticals Inc. The oldest executive at Constellation Pharmaceuticals Inc is James Audia, 64, who is the Director.
Emma's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Over the last 16 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... et Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include: